Engineered Tr1 cells designed for clinical use can eliminate primary pediatric AML blasts. Engineered Tr1 cells designed for clinical use can eliminate primary pediatric AML blasts

Purpose: To investigate the transcriptome of primary pediatric acute myeloid leukemia to identify molecular signatures correlated with sensitivity to LV-10 mediated killing Method: RNA sequencing of polyA enriched pediatric acute myeloid leukemia bone marrow aspirates Results: pAML killing sensitivity is associated with the expression of a myeloid maturation signature, while resistant pAMLs expressed a more stem cell-like signature Conclusions: Pediatric acute myeloid leukemia samples have different sensitivities to killing by LV-10 in vitro and the transcriptomes of killing-sensitive and killing-resistant lines differ Overall design: 14 primary pediatric acute myeloid leukemia bone marrow aspirates were incubated for 2h in complete X-VIVO15 supplemented with IL-3 (20 ng/mL, Peprotech) and G-CSF (20 ng/ml, Peprotech) at 10^6 cells/ml and then lysed for RNA sequencing